Lalezari Jacob P 4
4 · CytoDyn Inc. · Filed Mar 24, 2026
Research Summary
AI-generated summary of this filing
CytoDyn (CYDY) CEO Jacob Lalezari Receives 4.87M-Share Award
What Happened
Jacob P. Lalezari, CEO of CytoDyn, received an equity award of 4,874,691 shares (reported as a derivative acquisition) on March 20, 2026. The shares were granted at $0.00 (no cash paid) under the company’s 2012 Equity Incentive Plan; value to the holder depends on CytoDyn’s market price when/if the shares vest or are issued. This is a compensation grant (not an open‑market purchase or sale).
Key Details
- Transaction date: March 20, 2026; Form 4 filed March 24, 2026 (filed within required reporting window).
- Instrument/price: Grant/award (derivative) of 4,874,691 shares at $0.00.
- Vesting: 1,218,672 shares vest on March 20, 2027; remaining shares vest in approximately equal monthly installments from April 2027 through March 2030.
- Authorization: Approved by the Compensation Committee on March 20, 2026; uses shares reserved under the 2012 Equity Incentive Plan.
- Shares owned after transaction: Not specified in this filing.
- Filing timeliness: Filed March 24 for a March 20 grant — within the typical two business‑day Form 4 deadline.
Context
This is a standard executive compensation award subject to multi‑year vesting, meaning the CEO does not receive fully vested, tradable shares immediately. Such grants are routine for retaining executives and do not by themselves indicate immediate buying or selling pressure. Because the award is derivative/subject to vesting, the economic benefit depends on future company performance and share price at vesting.
Insider Transaction Report
- Award
Non-qualified stock option (right to buy)
[F1][F2]2026-03-20+4,874,691→ 4,874,691 totalExercise: $0.28Exp: 2036-03-20→ Common Stock (4,874,691 underlying)
Footnotes (2)
- [F1]This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
- [F2]1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.